CERT Stock - Certara, Inc.
Unlock GoAI Insights for CERT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $385.15M | $354.34M | $335.64M | $286.10M | $243.53M |
| Gross Profit | $230.63M | $213.31M | $203.07M | $174.49M | $142.76M |
| Gross Margin | 59.9% | 60.2% | 60.5% | 61.0% | 58.6% |
| Operating Income | $-1,731,000 | $-40,774,000 | $32.52M | $13.58M | $-24,420,000 |
| Net Income | $-12,051,000 | $-55,357,000 | $14.73M | $-13,266,000 | $-49,397,000 |
| Net Margin | -3.1% | -15.6% | 4.4% | -4.6% | -20.3% |
| EPS | $-0.08 | $-0.35 | $0.09 | $-0.09 | $-0.32 |
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Visit WebsiteEarnings History & Surprises
CERTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | $0.12 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.11 | $0.14 | +27.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.10 | $0.07 | -30.0% | ✗ MISS |
Q2 2025 | May 5, 2025 | $0.13 | $0.14 | +7.7% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.13 | $0.15 | +15.4% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.11 | $0.13 | +18.2% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.11 | $0.07 | -36.4% | ✗ MISS |
Q2 2024 | May 7, 2024 | $0.10 | $0.10 | 0.0% | = MET |
Q1 2024 | Feb 29, 2024 | $0.11 | $0.09 | -18.2% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $0.11 | $0.11 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $0.13 | $0.12 | -7.7% | ✗ MISS |
Q2 2023 | May 8, 2023 | $0.12 | $0.12 | 0.0% | = MET |
Q1 2023 | Mar 1, 2023 | $0.14 | $0.16 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.11 | $0.10 | -9.1% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $0.11 | $0.09 | -18.2% | ✗ MISS |
Q2 2022 | May 5, 2022 | $0.11 | $0.11 | 0.0% | = MET |
Q1 2022 | Mar 1, 2022 | $0.09 | $0.01 | -88.9% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $0.06 | $0.07 | +16.7% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.05 | $0.03 | -40.0% | ✗ MISS |
Q2 2021 | May 6, 2021 | $0.04 | $0.06 | +34.8% | ✓ BEAT |
Latest News
Frequently Asked Questions about CERT
What is CERT's current stock price?
What is the analyst price target for CERT?
What sector is Certara, Inc. in?
What is CERT's market cap?
Does CERT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CERT for comparison